Intravitreal bevacizumab or intravitreal ziv-aflibercept is given preoperatively at various time intervals and doses.
informational and educational purposes only.
Dive into the research topics of 'Intraocular pharmacokinetics of 10-fold intravitreal ranibizumab injection dose in rabbits'.
Translational Relevance: Our results highlight the potential for clinical application of a high-dose (10-fold) of anti-VEGF agents to prolong the intravitreal injection intervals, simultaneously improving the drug efficacy.AB - Purpose: To investigate intraocular pharmacokinetics of 10-fold dose of intravitreally injected ranibizumab compared with the conventional dose in an experimental model.
Similarly, the estimated time for ranibizumab concentration in the retina over 27 ng/mL (minimum effective concentration of ranibizumab) was prolonged approximately twice with the 10-fold dose (1315 h [55 days] vs. 2393 h [100 days]). Administration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses 13-times the predicted human exposure (based on maximal serum trough levels [Cmax]) after a single eye treatment at the recommended clinical dose The American Diabetes Association (ADA) recommends an intravitreous anti-vascular endothelial growth factor (anti-VEGF) agent, such as ranibizumab, as first-line therapy for the management of eyes with central-involved diabetic macular edema (CIDME).
Ranibizumab concentrations in the aqueous humor, vitreous, and retina were estimated at each time period after injection, using enzyme-linked immunosorbent assay.
Conclusions: The retinal half-life and concentration of ranibizumab in rabbit eyes were increased approximately twice after a 10-fold dose compared with the conventional dose. By continuing you agree to the /viewarticle/936461
Indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD)0.5 mg (0.05 mL of 10 mg/mL solution) intravitreal qMonth (~q28 days)May give q3month after 3 or 4 monthly injections (if continued monthly dosing not feasible) but is less effective than once monthly dosingIndicated for macular edema following retinal vein occlusion0.5 mg (0.05 mL of 10 mg/mL solution) intravitreal injection qMonth (~q28 days) x6 months0.3 mg (0.05 mL of 6 mg/mL solution) intravitreally qMonth (~q28 days)Indicated for treatment of diabetic retinopathy in patients with or without diabetic macular edema (DME)0.3 mg (0.05 mL of 6 mg/mL solution) intravitreally qMonth (~q28 days)Indicated for treatment of myopic choroidal neovascularization (mCNV)0.5 mg (0.05 mL of 10 mg/mL solution) intravitreal injection qMonth initially, for up to 3 monthsMay retreat if needed, based on assessment of mean baseline change in visual acuity (BCVA)Ocular: Tear of retinal pigment epithelium among patients with neovascular AMDRisk of endophthalmitis or retinal detachment with intravitreous injectionsPossibility of IOP increase within 60 min of intravitreal injectionPotential for adverse thromboembolic events (eg, nonfatal stroke, nonfatal MI, vascular death)Fatal events occurred more frequently in patients with diabetic macular edema and diabetic retinopathy at baseline, who were treated monthly compared with controlNo studies on effects of ranibizumab on fertility conducted; not known whether ranibizumab can affect reproduction capacity; based on anti-VEGF mechanism of action for ranibizumab, therapy may pose risk to reproductive capacityThere are no adequate and well-controlled studies in pregnant womenAdministration of ranibizumab to pregnant monkeys throughout the period of organogenesis resulted in a low incidence of skeletal abnormalities at intravitreal doses 13-times the predicted human exposure (based on maximal serum trough levels [Cmax]) after a single eye treatment at the recommended clinical doseRanibizumab should be given to a pregnant woman only if clearly neededThere are no data available on presence of ranibizumab in human milk; effects of ranibizumab on breastfed infant or effects of ranibizumab on milk production/excretion; developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from ranibizumabA: Generally acceptable.
Methods: Ranibizumab 30 μL at 10 mg/mL (conventional) and 100 mg/mL (10-fold) doses was injected separately into each eye of 28 rabbits.